How PlexusDx Weight Management Protocols compare to the major cash-pay GLP-1 programs in 2026 — Mochi, Eden, MEDVi, Ro, GoodRx Care Direct, NovoCare, and LillyDirect — on price, medication source, membership fees, and total annualized cost.

Compounded tirzepatide provider rankings cycle through MEDVi, Eden, Yucca Health, Willow, and TrimRx. PlexusDx Tirzepatide Injection ($289/mo) and Tirzepatide Oral ($349/mo) compare on price, oversight, and genetic-test personalization.

A buyer-side read of the seven brand-name GLP-1 telehealth providers (Ro, Walgreens, GoodRx, Hims & Hers, PlushCare, Sesame, WeightWatchers) covering true month-one cost, what each dispenses, and how PlexusDx compounded protocols ($129/mo to $349/mo, all-inclusive, no membership) fit when branded coverage isn't accessible.

"Zepbound coupon" splits into two questions: the manufacturer savings card and independent pharmacy discounts. This guide explains who each helps, why they rarely stack, how coverage and the compounded pathway fit, and the genetic context PlexusDx adds underneath the decision.

Most "Zepbound vs tirzepatide" searches are naming questions rather than true comparisons. This article explains that Zepbound is the brand and tirzepatide the active ingredient, why one molecule carries several brand names, and why that distinction drives coverage and cost.

Zepbound is Eli Lilly's tirzepatide brand for chronic weight management (2023) and obstructive sleep apnea (2024) — it is NOT FDA-approved for type 2 diabetes. Mounjaro is the same molecule separately approved for diabetes. This article explains the brand distinction, April 2026 cost, and the FTO, TCF7L2, and MC4R genetic architecture.

Zepbound is Eli Lilly's brand name for tirzepatide — the same GIP/GLP-1 dual agonist active ingredient as Mounjaro, but labeled for chronic weight management (2023) and obstructive sleep apnea (2024). This article covers the brand-vs-drug-name relationship, FDA indications, April 2026 pricing, and the FTO/GLP1R/MC4R genetic architecture underneath.

Zepbound and Mounjaro are the same tirzepatide molecule from Eli Lilly, separated only by the FDA indication each brand carries. This editorial comparison, current as of April 2026, explains the labeling split, the SURMOUNT and SURPASS evidence, list prices, and the shared genetics.

Mounjaro and Zepbound share a single tirzepatide molecule sold under two Eli Lilly labels. This independent comparison explains why one manufacturer uses two brand names, how their FDA indications and trials diverge, how they are priced as of April 2026, and why the underlying genetics stay identical either way.

Zepbound and Ozempic are different molecules with different receptor strategies: tirzepatide adds a GIP arm that semaglutide lacks. This editorial comparison, current as of April 2026, weighs their approved uses, SURMOUNT and SUSTAIN evidence, list prices, and shared genetic terrain.

Wegovy and Zepbound are the two injectables FDA-approved specifically for chronic weight management, making this a rare like-for-like comparison. This independent review sets single-hormone semaglutide against dual-hormone tirzepatide on action, labels, evidence, safety, and cost, then the genetics both share as a common starting line.

Zepbound's published list price is about $1,059 per month as of April 2026, but insurance, the prescribed indication, savings cards, and pharmacy coupons all reshape that figure. This overview explains each factor and the genetic context PlexusDx places upstream of any protocol.